Pharmacology and pharmacokinetics of 5-aminosalicylic acid-Reference-Cited by-同舟云学术

Pharmacology and pharmacokinetics of 5-aminosalicylic acid

Published:1987-12 Issue:S12 Volume:32 Page:S46-S50
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Digest Dis Sci

Author:

Klotz U.,Maier K. E.

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/BF01312463.pdf

Reference30 articles.

1. Klotz U: Clinical efficacy of oral 5-aminosalicylic acid in the treatment of inflammatory bowel disease. Am J Gastroenterol 80:660, 1985

2. Friedman G: Sulfasalazine and new analogues. Am J Gastroenterol 81:141?144, 1986

3. Klotz U: Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10:285?302, 1985

4. Klotz U, Maier KE, Fischer C, Bauer KH: A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease: Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneim-Forsch 35:636?639, 1985

5. Azad Khan KA, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet II:892?895, 1977

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-induced nephrolithiasis and crystalluria: the particular case of the sulfasalazine derivatives;Comptes Rendus. Chimie;2021-09-17

2. Toxicity of Gold Nanoparticles in Mice due to Nanoparticle/Drug Interaction Induces Acute Kidney Damage;Nanoscale Research Letters;2020-07-02

3. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis;Clinical Pharmacokinetics;2018-05-12

4. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease;Clinical Pharmacokinetics;2018-03-06

5. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease;European Journal of Pharmacology;2016-08